Luc Mercken
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Luc Mercken has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
André Delacourte
INSERM U422, Lille, France
1 shared publication- Benoît Delatour
Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, APHP, Hôpital de la Pitié Salpêtrière, Paris, France
1 shared publication Brigitte Schombert
Functional Genomic, Aventis, Vitry‐sur‐Seine, France
1 shared publicationCharles Duyckaerts
Laboratory of Neuropathology and Inserm U289, La Salpêtrière Hospital, Paris, France
1 shared publication- Cristine Alves da Costa
Institut de Pharmacologie Moléculaire et Cellulaire
1 shared publication Cécile Dumanchin‐Njock
Institut de Pharmacologie Moléculaire et Cellulaire, CNRS, Université de Nice-Sophia Antipolis, Valbonne, France
1 shared publication
Latest Publications
- Open Access
- 2 March 2005
- Published by Wiley in Journal of Neurochemistry
- Vol. 93 (2) , 330-338
Expression of human FE65 in amyloid precursor protein transgenic mice is associated with a reduction in β‐amyloid load
FE65 is an adaptor protein that interacts with the cytoplasmic tail of the amyloid precursor protein (APP). In cultured non‐neuronal cells, the formation of the FE65‐APP complex is a key element for the modulation of APP processing, signalling and β‐amyloid (Aβ) production. The functions of FE65 in vivo, including its role in the metabolism of neuronal APP, remain to be investigated. In this study, transgenic mice expressing human FE65 were generated and crossbred with APP transgenic mice, known to develop Aβ deposits at 6 months of age. Compared with APP mice, APP/FE65 double transgenic mice exhibited a lower Aβ accumulation in the cerebral cortex as demonstrated by immunohistochemistry and immunoassay, and a lower level of APP‐CTFs. The reduced accumulation of Aβ in APP/FE65 double transgenics, compared with APP mice, could be linked to the low Aβ42 level observed at 4 months of age and to the lower APP‐CTFs levels. The present work provides evidence that FE65 plays a role in the regulation of APP processing in an in vivo model.
- 2 March 2005
- Published by Wiley in Journal of Neurochemistry
- Vol. 93 (2) , 330-338
Open AccessExpression of human FE65 in amyloid precursor protein transgenic mice is associated with a reduction in β‐amyloid load
FE65 is an adaptor protein that interacts with the cytoplasmic tail of the amyloid precursor protein (APP). In cultured non‐neuronal cells, the formation of the FE65‐APP complex is a key element for the modulation of APP processing, signalling and β‐amyloid (Aβ) production. The functions of FE65 in vivo, including its role in the metabolism of neuronal APP, remain to be investigated. In this study, transgenic mice expressing human FE65 were generated and crossbred with APP transgenic mice, known to develop Aβ deposits at 6 months of age. Compared with APP mice, APP/FE65 double transgenic mice exhibited a lower Aβ accumulation in the cerebral cortex as demonstrated by immunohistochemistry and immunoassay, and a lower level of APP‐CTFs. The reduced accumulation of Aβ in APP/FE65 double transgenics, compared with APP mice, could be linked to the low Aβ42 level observed at 4 months of age and to the lower APP‐CTFs levels. The present work provides evidence that FE65 plays a role in the regulation of APP processing in an in vivo model.
- 1 September 2001
- Published by Wiley in Journal of Neurochemistry
- Vol. 78 (5) , 1153-1161
The caspase‐derived C‐terminal fragment of βAPP induces caspase‐independent toxicity and triggers selective increase of Aβ42 in mammalian cells
During its physiopathological maturation, the β-amyloid precursor protein undergoes several distinct proteolytic events by activities called secretases. In Alzheimer's disease, the main histological hallmark called senile plaque is clearly linked to the overproduction of the amyloid peptides Aβ40 and Aβ42, two highly aggregable βAPP-derived fragments generated by combined cleavages by β- and γ-secretases. Recently, an alternative hydrolytic pathway was described, involving another category of proteolytic activities called caspases, responsible for the production of a 31 amino acids βAPP C-terminal fragment called C31. C31 was reported to lower the viability of N2a cells but the exact mechanisms mediating C31-toxicity remained to be established. Here we show that the transient transfection of pSV2 vector encoding C31 lowers by about 80% TSM1 neuronal cells viability. Arguing against a C31-stimulated apoptotic response, we demonstrate by combined enzymatic and immunological approaches that C31 expression did not modulate basal or staurosporine-induced caspase 3-like activity and pro-caspase-3 activation. Furthermore, C31 did not modify Bax and p53 expressions, poly-(ADP-ribose)-polymerase cleavage and cytochrome c translocation into the cytosol. However, we established that C31 overexpression triggers selective increase of Aβ42 but not Aβ40 production by HEK293 cells expressing wild-type βAPP751. Altogether, our data demonstrate that C31 induces a caspase-independent toxicity in TSM1 neurons and potentiates the pathogenic βAPP maturation pathway by increasing selectively Aβ42 species in wild type-βAPP-expressing human cells.
- 1 September 2001
- Published by Wiley in Journal of Neurochemistry
- Vol. 78 (5) , 1153-1161
The caspase‐derived C‐terminal fragment of βAPP induces caspase‐independent toxicity and triggers selective increase of Aβ42 in mammalian cells
During its physiopathological maturation, the β-amyloid precursor protein undergoes several distinct proteolytic events by activities called secretases. In Alzheimer's disease, the main histological hallmark called senile plaque is clearly linked to the overproduction of the amyloid peptides Aβ40 and Aβ42, two highly aggregable βAPP-derived fragments generated by combined cleavages by β- and γ-secretases. Recently, an alternative hydrolytic pathway was described, involving another category of proteolytic activities called caspases, responsible for the production of a 31 amino acids βAPP C-terminal fragment called C31. C31 was reported to lower the viability of N2a cells but the exact mechanisms mediating C31-toxicity remained to be established. Here we show that the transient transfection of pSV2 vector encoding C31 lowers by about 80% TSM1 neuronal cells viability. Arguing against a C31-stimulated apoptotic response, we demonstrate by combined enzymatic and immunological approaches that C31 expression did not modulate basal or staurosporine-induced caspase 3-like activity and pro-caspase-3 activation. Furthermore, C31 did not modify Bax and p53 expressions, poly-(ADP-ribose)-polymerase cleavage and cytochrome c translocation into the cytosol. However, we established that C31 overexpression triggers selective increase of Aβ42 but not Aβ40 production by HEK293 cells expressing wild-type βAPP751. Altogether, our data demonstrate that C31 induces a caspase-independent toxicity in TSM1 neurons and potentiates the pathogenic βAPP maturation pathway by increasing selectively Aβ42 species in wild type-βAPP-expressing human cells.